Kiniksa Pharmaceuticals Gets Consensus 'Buy' Recommendation from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has received a consensus recommendation of "Buy" from a group of five research firms. According to MarketBeat.com, analysts covering the company have issued ratings that all favor buying the stock. The average target price for Kiniksa Pharmaceuticals over the next twelve months is projected to be $36.60.

Recently, multiple analysts have published reports regarding Kiniksa and its stock performance. Notably, Evercore ISI raised their price target from $30.00 to $35.00, designating the stock as "outperform" in their report dated October 30th. Likewise, JPMorgan Chase & Co. increased their target price from $39.00 to $40.00 and provided an "overweight" rating on November 5th. Additionally, Jefferies Financial Group began coverage on Kiniksa Pharmaceuticals on September 13th, giving it a "buy" rating and specifying a price target of $40.00.

Insider Transactions

In related insider activity, COO Eben Tessari sold 17,500 shares of Kiniksa on September 23rd, receiving an average price of $24.99 per share, yielding a total of $437,325.00. Post-sale, he retains 116,975 shares valued at approximately $2.9 million, marking a decrease of 13.01% in his holdings. This sale was documented in a filing with the Securities and Exchange Commission. Furthermore, CFO Mark Ragosa sold 8,969 shares on December 3rd at an average price of $21.45, resulting in a transaction of $192,385.05. Following this sale, he holds 22,958 shares valued around $492,449.10, decreasing his position by 28.09%. Over the past three months, insiders have sold a total of 44,592 shares for approximately $1.11 million. Insiders collectively hold 54.57% of the company's stock.

Institutional Investments

Several hedge funds have modified their positions in Kiniksa Pharmaceuticals recently. Quarry LP established a new investment in the third quarter worth around $50,000. CWM LLC boosted their stake significantly by 443.0%, now owning 2,449 shares valued at $61,000 after acquiring an additional 1,998 shares. nVerses Capital LLC also entered a new position valued at $80,000 during the third quarter. Other new investors include Ashton Thomas Private Wealth LLC, which bought shares worth $100,000 in Q2, and Lynx1 Capital Management LP, acquiring shares valued at $177,000. Currently, 53.95% of Kiniksa Pharmaceuticals is owned by institutional investors.

Kiniksa Pharmaceuticals Stock Performance

The stock of Kiniksa Pharmaceuticals opened at $20.59 on Friday, having a 1-year low of $16.56 and a high of $28.15. The company boasts a market capitalization of $1.49 billion, a price-to-earnings ratio of -147.06, and a beta of 0.27. The 50-day moving average stands at $22.79, while the 200-day moving average is $23.09.

In its latest quarterly earnings, released on October 29th, Kiniksa Pharmaceuticals reported a loss of $0.18 per share, falling short of the consensus estimate of a loss of $0.01 per share by $0.17. The company's return on equity is negative at -7.31%, with a net margin of -2.36%. For the quarter, Kiniksa achieved revenues of $112.21 million, slightly above analyst expectations of $111.51 million. This revenue represents a 67.4% increase from the same quarter last year. Looking ahead, analysts predict that Kiniksa Pharmaceuticals will post an average loss of $0.55 per share for the current fiscal year.

Company Overview

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for diseases with significant unmet needs globally. Their product pipeline includes ARCALYST, which treats recurrent pericarditis, Mavrilimumab for giant cell arteritis, Vixarelimab aimed at prurigo nodularis, and KPL-404 targeting a T-cell co-stimulatory signal critical for immune responses.

Kiniksa, Pharmaceuticals, Buy